

**WUXI BIOLOGICS (CAYMAN) INCORPORATED:
THIS HISTORIC FLOTATION SAW ONE OF ITS FOUNDERS
ENRICHED BY ONE QUARTER OF A BILLION DOLLARS**

**This Pharmaceutical Company Is, Today,
Without Any Material Debts**

The flotation of WuXi Biologics (Cayman) Incorporated () (Code: 2269, Main Board, The Stock Exchange of Hongkong Ltd) on the premier equity market of the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC) set a 2017 record for a number of reasons that included:

1. The Company raised \$HK3,904,700,000 by selling 199,065,057 New Shares to the Investing Public;
2. Its share price continued to be a relatively hot counter on the Main Board of The Stock Exchange of Hongkong Ltd for some time after the commencement of share trading that took place on Tuesday, June 13, 2017; and,
3. The Non-Executive Chairman, Dr Li Ge (), walked away with \$HK211.69 million, gross, by the sales of his 10,276,031 Shares, while his wife, Dr Zhao Ning (), grossed another \$HK37.85 million by the sales of her 1,857,590 Shares. Thus, this husband-and-wife team of Dr Li Ge and Dr Zhao Ning was enriched to the extent of \$HK249.54 million, before costs, thanks to this flotation.

The **Initial Public Offering (IPO)** of this pharmaceutical company, operating exclusively in the PRC, proper, as opposed to the HKSAR of the PRC, has to be considered among the record-setting IPOs of the territory in terms of the amount of money that a single company has been raised, to say the least.

Whether or not the Company is deserving of this accolade on its entrance on the one of the world's most-successful equity markets, only time will tell.

The IPO Of WuXi Biologics (Cayman) Incorporated

The Global Offering of WuXi Biologics (Cayman) Incorporated was, initially, the sales of 192,982,500, \$US0.000025 New Shares at the Indicative Offer Price Per Share, ranging from \$HK18.60 to \$HK20.60.

However, on June 14, 2017, Management announced that there had been a full exercise of the Over-Allotment Option of 28,947,000 Shares, raising the total number of New Shares to be sold to investors to 199,065,057.

The Company shall be netting, in aggregate, about \$HK3,904,700,000 from this 2017, record-setting IPO in the HKSAR on the assumption that the entire 28,947,000 Over-Allotment Option Shares find qualified buyers – which appears to be an almost certainty, all things considered.

The utilisation of the net proceeds with regard to the sales of the 199,065,057 New Shares of the Company was given at Pages 296 and 297 of the Global Offering Prospectus, dated May 31, 2017:

1. Approximately, 45.10 percent of the net proceeds, that is about \$HK1,761,019,700, 'will

be used to repay all of our outstanding bank facilities, including (i) a five-year syndicated term loan granted by Shanghai Pudong Development Bank Baoshan Branch () and Ping An Bank Shanghai Branch (), which bears the relevant benchmark interest rate published by the PBOC (the People's Bank of China []) (being 4.75% as of the Latest Practicable Date – May 22, 2017) and will mature in May 2021, (ii) a three-year syndicated term loan granted by Shanghai Pudong Development Bank Baoshan Branch and Ping An Bank Shanghai Branch, which bears the relevant benchmark interest rate published by the PBOC (being 4.75% as of the Latest Practicable Date) and will mature in May 2019 and (iii) a one-year credit facility granted by HSBC (The Hongkong and Shanghai Banking Corporation Ltd), which bears an interest rate of LIBOR (London Interbank Offered Rate) plus 1.0% per annum and will mature in March 2018 ... ';

2. *Approximately, 44.90 percent of the net proceeds, that is about \$HK1,753,210,300, 'will be used for the construction of our new facilities and existing facility improvement and maintenance. We expect to use approximately HK\$645.9 million of the net proceeds for our expansions, including (i) approximately HK\$73.1 million and HK\$107.3 million on the construction and equipment purchase for the new facilities at our Wuxi site, respectively, and (ii) approximately HK\$130.0 million and HK\$335.5 million on the construction and equipment purchase for the new facilities at our Shanghai site, respectively ... ';* and,
3. *Approximately, 10.00 percent of the net proceeds, that is about \$HK390.47 million, 'will be used for our working capital and other general corporate purposes'.*

In addition ... [CLICK TO ORDER FULL ARTICLE](#)

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which they have read in TARGET, please feel free to e-mail your views to editor@targetnewspapers.com. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.